Fingolimod and Fludrocortisone interaction

Fingolimod and Fludrocortisone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Fludrocortisone (Fludrocortisone Acetate) label · effective 2026-05-06

Major

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids.

Warningsby drug classView label on DailyMed
Major

Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles and, if exposed, to obtain medical advice.

Precautionsby drug classView label on DailyMed
Minor

Children who are on immunosuppressant drugs are more susceptible to infections than healthy children.

Warningsby drug classView label on DailyMed

From the Fingolimod (Gilenya) label · effective 2026-07-22

Moderate

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Concomitant use of GILENYA with any of these therapies, and also with corticosteroids, would be expected to increase the risk of immunosuppression [see Drug Interactions (7.4)] .

Warnings and precautionsby drug classView label on DailyMed
Moderate

Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA.

Drug interactionsby drug classView label on DailyMed
Minor

Prior and Concomitant Treatment with Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies In clinical studies, patients who received GILENYA did not receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS.

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.